Hers for Hair Loss, Read From the Company's Own Filings

We could not read forhers.com. On 24 September 2026, every automated request to the site — plain fetch, text-rendering proxy and a real headless browser — was stopped by a bot check. So this page carries no Hers prices, because we did not see them, and a price we did not read is a price we will not print.

What we could read is better anyway: the annual report that Hims & Hers Health, Inc. — the company behind both the Hims and Hers brands — filed with the US Securities and Exchange Commission on 23 February 2026, for the year ended 31 December 2025. A company writes very differently when the audience is a regulator, and four things in that document tell you more about what you are buying than any landing page would.

Who actually prescribes

Not the company. The filing explains that because a majority of US states prohibit the corporate practice of medicine, the company has contractual arrangements with what it calls Affiliated Medical Groups — "separate professional corporations or other professional entities owned solely by licensed" physicians — which provide the clinical services to customers.

That structure is normal, legal and used across telehealth. It is also the answer to "who is responsible for the prescribing decision": a licensed clinician in a separate professional entity, not the retailer whose brand is on the box. It is worth knowing which one you are talking to when something goes wrong, and which one holds your medical record.

The filing also states plainly that providers prescribing on the platform are permitted to prescribe drugs "for 'off-label' uses (i.e., uses not approved by the FDA and not described in the product's labeling) because the FDA generally does not regulate the practice of medicine". For women's hair loss, that sentence is not hypothetical: several of the medicines used in this field are off-label in women, which is why what off-label actually means for oral minoxidil and what the finasteride label reports about women are worth reading before a questionnaire, not after.

What "compounded" means in the small print

The company discloses that certain products on its platform are compounded drug products under Section 503A or Section 503B of the Federal Food, Drug and Cosmetic Act, and describes those sections as providing "exemptions from the requirements for preapproval to market a new drug and labeling with adequate directions for use".

Read that twice, because it is the whole point. A compounded product is not an FDA-approved product; it is one made for a patient under an exemption from that approval requirement. The filing lists the company's own facilities: two licensed 503A pharmacies, two pharmacies licensed by the UK's General Pharmaceutical Council, a licensed 503B outsourcing facility, a peptide manufacturing facility and a laboratory facility.

None of that is a scandal, and compounding has real uses. But "personalised formula" on a marketing page and "exempt from preapproval" in an annual report describe the same object, and only one of those phrasings tells you what the regulator did and did not check.

How the billing actually works

The subscription mechanics are described with a precision no checkout page matches. Beyond a 30-day cadence, customers can choose shipment cadences or treatment terms "from every 60 days to 360 days, depending on the offering". Customers are billed on a recurring basis for the selected cadence, and with the exception of prepaid offerings, are typically billed on each shipment. Subscribers can "cancel or snooze Subscriptions in between billing periods" and reactivate later.

One clause is worth carrying to the checkout with you: the filing notes that subscribers may sometimes be charged, and products shipped, earlier than their regularly scheduled cadence, to accommodate holidays or for other operational reasons. If you are budgeting a subscription to the month, that is the sentence to remember.

What the brand sells that is not a medicine at all

The filing describes over-the-counter drug and device products, cosmetics and supplements, many of them "white-labeled" — the manufacturer's product sold under the Hims & Hers brand, or co-branded with the manufacturer. Several are developed with manufacturers with input from the company's internal product research team.

So a single basket can contain three different regulatory categories: an approved drug, a compounded preparation exempt from preapproval, and a cosmetic or supplement with no hair-loss approval at all. They arrive in the same box, in the same brand's typography, at one monthly price. Knowing which is which is the buyer's job, and the filing is where the company says so.

What we cannot tell you, and will not guess

We have no Hers prices, no current product list, no cancellation screenshots and no terms page, because the site would not serve any of them to us. Several review sites publish figures for Hers; we have not verified them at the source and will not repeat them. When the site becomes readable, this page will be updated with what is actually on it, and dated.

If you want to look for yourself, their own page is the place — and be aware that it is marked as a partner link on this site. No programme has approved this domain, so today that link pays us nothing; if that ever changes, nothing on this page changes with it, because none of the above came from them.

How to read any women's hair-loss service

The four disclosures above generalise, and they make a decent checklist for any service of this kind:

1. Who prescribes, and are they a separate clinical entity? Ask who holds your record and who you complain to.
2. Which products are compounded, and which are approved? The words "personalised" and "custom" often mark the former.
3. What is the billing cadence, and what triggers an early charge? Read the terms, not the price.
4. Is there anything in the basket that is a cosmetic or supplement? Those are not treatments, whatever the bundle implies.

A service that answers all four in plain language is doing something right. One that answers none of them until you have entered a card is telling you something too.

And before any of it: a subscription is a way to reach a clinician, not a diagnosis. If nobody has established why your hair is thinning, every hair-loss treatment for women, graded by what was tested in women is the right page to start from, and its first section is about the appointment rather than the purchase.